Glofitamab in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): durable complete responses and manageable safety observed at clinically relevant doses in Phase I dose escalation

被引：0
|
作者：
Hutchings, M. [1 ]
Morschhauser, F. [2 ]
Iacoboni, G. [3 ]
Carlo-Stella, C. [4 ]
Offner, F. C. [5 ]
Sureda, A. [6 ]
Salles, G. [7 ,8 ]
Martinez-Lopez, J. [9 ]
Crump, M. [10 ]
Lundberg, L. [11 ]
Dixon, M. [12 ]
Kwan, A. [13 ]
Wei, M. C. [13 ]
Broeske, A-M E. [14 ]
Carlile, D. [12 ]
O'Hear, C. [13 ]
Dickinson, M. J. [15 ,16 ]
机构：
[1] Rigshosp Copenhagen, Dept Oncol, Copenhagen, Denmark
[2] Ctr Hosp Reg Univ Lille, Lille, France
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Humanitas Univ, Milan, Italy
[5] Univ Ziekenhuis Gent, Ghent, Belgium
[6] Inst Catala Oncol Hospitalet, Barcelona, Spain
[7] Hosp Civils Lyon, Pierre Benite, France
[8] Univ Claude Bernard, Pierre Benite, France
[9] Hosp Univ 12 Octubre H12O, Madrid, Spain
[10] Princess Margaret Hosp, Toronto, ON, Canada
[11] F Hoffmann La Roche Ltd, Basel, Switzerland
[12] Roche Prod Ltd, Welwyn Garden City, Herts, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Roche Pharma Res & Early Dev, Roche Innovat Ctr, Penzberg, Germany
[15] Royal Melbourne Hosp, Melbourne, Vic, Australia
[16] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226
引用
收藏
页码：58 / 59
页数：2
相关论文
共 50 条
  • [1] Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial
    Korfi, Koorosh
    Christiansen, Ailsa
    Jiang, Zhiwen
    Wilson, Sabine
    Tracy, Samuel
    Blank, Annika
    Herter, Sylvia
    Dimier, Natalie
    Gomes, Bruno
    Umana, Pablo
    Ghesquieres, Herve
    Houot, Roch
    Offner, Fritz
    Walter, Harriet
    Bartlett, Nancy L.
    Cartron, Guillaume
    Dickinson, Michael
    Townsend, William
    Gritti, Giuseppe
    Albareda, Francesc Bosch
    Morschhauser, Franck
    Hutchings, Martin
    Carlo-Stella, Carmelo
    Lechner, Katharina
    BLOOD, 2023, 142
  • [2] A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
    Hernandez-Ilizaliturri, Francisco J.
    Flinn, Ian W.
    Kuruvilla, John
    Assouline, Sarit E.
    Ulrickson, Matthew L.
    Christian, Beth A.
    Landsburg, Daniel J.
    Stuart, Monic
    Lowman, Henry
    Levin, Nancy
    BLOOD, 2020, 136
  • [3] Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non- Hodgkin Lymphoma (NHL) Patients (pts)
    Dickincon, Michael
    Carlo-Stella, Carmelo
    Morschhauser, Franck
    Patel, Krish
    Khan, Cyrus
    Barlett, Nancy L.
    Iacoboni, Gloria
    Hertzberg, Mark
    Leppa, Sirpa
    Van Den Neste, Eric
    Tani, Monica
    Cartron, Guillaume
    Perez-Callejo, David
    Lundberg, Linda
    Relf, James
    Clark, Emma
    Humphrey, Kathryn
    Hutchings, Martin
    BLOOD, 2021, 138
  • [4] Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study
    Bartlett, Nancy L.
    Dickinson, Michael
    Hutchings, Martin
    Carlo-Stella, Carmelo
    Wu, Shang-Ju
    Leppa, Sirpa
    Trneny, Marek
    Corradini, Paolo
    Offner, Fritz
    Mulvihill, Estefania
    Bottos, Alessia
    Chohan, Saibah
    Baumlin, Pauline
    Relf, James
    Lundberg, Linda
    Bachy, Emmanuel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Phase I study of CC-90010 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Moreno, Victor
    Brana, Irene
    Sepulveda Sanchez, Juan Manuel Manuel
    Vieito Villar, Maria
    Hernandez-Guerrero, Tatiana
    Doger, Bernard
    Saavedra, Omar
    Ferrero, Olga
    Sarmiento, Rafael
    Arias, Marina
    De Alvaro, Juan
    DiMartino, Jorge F.
    Zuraek, Marlene
    Sanchez Perez, Tania
    Filvaroff, Ellen
    Aronchik, Ida
    Lamba, Manisha
    Hanna, Bishoy
    Nikolova, Zariana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Phase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Moreno, V.
    Brana, I.
    Sepulveda Sanchez, J. M.
    Vieito Villar, M.
    Hernandez-Guerrero, T.
    Doger, B.
    Saavedra, O.
    Italiano, A.
    Michot, J-M.
    Musuraca, G.
    Asierto, P. A.
    Carlo-Stella, C.
    Sarmiento, R.
    De Alvaro, J.
    Di Martino, J.
    Zuraek, M.
    Sanchez Perez, T.
    Filvaroff, E.
    Hanna, B.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 438 - 438
  • [7] Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J. S.
    Plummer, R.
    Isambert, N.
    Martin-Romano, P.
    Baudin, E.
    Mora, S.
    Filvaroff, E.
    Lamba, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2019, 30 : 9 - 9
  • [8] Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
    Hollebecque, A.
    de Bono, J.
    Plummer, R.
    Isambert, N.
    Martin-Romano, P.
    Baudin, E.
    Mora, S.
    Harding, A.
    Nguyen, A.
    Filvaroff, E.
    Lamba, M.
    Liu, K.
    De Alvaro, J.
    DiMartino, J.
    Zuraek, M.
    Nikolova, Z.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] A Phase I Dose-Escalation Trial of Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
    Abramson, Jeremy S.
    Takvorian, Tak
    Jacobsen, Eric D.
    Brown, Jennifer R.
    Barnes, Jeffrey A.
    Feng, Yang
    Neuberg, Donna
    Hochberg, Ephraim P.
    BLOOD, 2010, 116 (21) : 740 - 740
  • [10] EFFICACY AND SAFETY OF DOSE-ADJUSTED EPOCH FOR RELAPSED AND REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
    Suzuki, T.
    Harada, Y.
    Matsubara, E.
    Aoki, T.
    Oyama, T.
    Kasai, M.
    Uchida, T.
    Ogura, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 107 - 107
12345